Orthofix Medical (OFIX)

• Market cap: $666M
• 1 day: 1.40%
• 5 days: -1.97%
• 1 month: -7.63%
• 3 months: 7.53%
• 6 months: 37.24%
• Year to date: 32.75%
• 1 year: 30.07%
• 5 years: -62.33%
• 10 years: -43.37%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Employees: 1,634

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

317% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 6

15% more funds holding

Funds holding: 130 [Q2] → 149 (+19) [Q3]

9% more capital invested

Capital invested by funds: $498M [Q2] → $542M (+$43.2M) [Q3]

2% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 47

9.34% less ownership

Funds ownership: 100.16% [Q2] → 90.82% (-9.34%) [Q3]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]

97% less call options, than puts

Call options by funds: $5K | Put options by funds: $199K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $22 26% upside
• Avg. target: $23 32% upside
• High target: $24 38% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Roth MKM Jason Wittes 55% 1-year accuracy 11 / 20 met price target	26% upside $22	Buy Reiterated	8 Nov 2024
Stifel Mathew Blackman 56% 1-year accuracy 9 / 16 met price target	38% upside $24	Buy Upgraded	8 Nov 2024